Aura Biosciences (NASDAQ:AURA) Issues Earnings Results, Beats Expectations By $0.08 EPS

Aura Biosciences (NASDAQ:AURA) announced its quarterly earnings results on Monday. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08, FiscalAI reports.

Aura Biosciences Stock Performance

Shares of NASDAQ AURA opened at $6.56 on Monday. Aura Biosciences has a 1 year low of $4.73 and a 1 year high of $9.53. The firm has a market cap of $680.30 million, a price-to-earnings ratio of -3.75 and a beta of 0.41. The stock’s 50-day simple moving average is $6.54 and its 200-day simple moving average is $6.72.

Analysts Set New Price Targets

A number of research analysts have commented on AURA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, October 12th. HC Wainwright lowered their target price on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Finally, Wall Street Zen downgraded Aura Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $17.50.

Aura Biosciences Company Profile

Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.

Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.